Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vapreotide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR2 known ✓ | P30874 | 16/20 | 0.81 |
| ▸ | SSTR5 known ✓ | P35346 | 15/20 | 0.81 |
| ▸ | SSTR3 known ✓ | P32745 | 8/20 | 0.78 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.78 |
| ▸ | SSTR4 | P31391 | 7/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vapreotide SCHEMBL6369050 | 1.00 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL29405608 | 1.00 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL4826 | 1.00 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL31632623 | 1.00 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL30163296 | 1.00 | SSTR2 (0.81) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL29580907 | 0.99 | SSTR2 (0.80) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL294911 | 0.99 | SSTR2 (0.80) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL29384009 | 0.99 | SSTR2 (0.80) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL5200070 | 0.97 | SSTR2 (0.78) | SSTR2SSTR5SSTR3SSTR1SSTR4 | |
| SCHEMBL23482743 | 0.97 | SSTR5 (0.78) | SSTR2SSTR5SSTR3SSTR1SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 15511 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| EP-4680203-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | Prolevi Bio AB (SE) | 2026-01-21 | — | — | EP | claimed |
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| EP-4673157-A2 | COMPOSITIONS FOR MODULATING GUT MICROFLORA POPULATIONS, TREATMENT OF DYSBIOSIS AND DISEASE PREVENTION, AND METHODS FOR MAKING AND USING SAME | Persephone Biosciences, Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| WO-2025264805-A2 | SYNBIOTICS FOR MODULATING GUT MICROFLORA POPULATIONS, TREATMENT OF DYSBIOSIS AND DISEASE PREVENTION, AND METHODS FOR MAKING AND USING SAME | PERSEPHONE BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | claimed |
| US-20250387523-A1 | COMBINATION THERAPY OF RADIONUCLIDE COMPLEX | NOVARTIS AG (CH) | 2025-12-25 | — | — | US | claimed |
| WO-2025188678-A9 | ICAM-1 TARGETED CAR CONSTRUCTS AND METHODS OF TREATMENT | AffyImmune Therapeutics Inc. (US) | 2025-11-27 | — | — | WO | claimed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | claimed |
| EP-0808153-B1 | METHOD AND DEVICE FOR ADMINISTERING ANALGESICS | MEDTRONIC INC (US) | 1999-08-04 | — | — | EP | claimed |
| WO-1999026551-A1 | METHOD TO ENHANCE TISSUE ACCUMULATION OF RADIOLABELED COMPOUNDS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 1999-06-03 | — | — | WO | claimed |
| EP-0896544-A1 | COMBINATION OF A SOMATOSTATIN ANALOGUE AND A RAPAMYCIN | Novartis AG (CH) | 1999-02-17 | — | — | EP | claimed |
| EP-0896527-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE SUSTAINED RELEASE OF INSOLUBLE ACTIVE PRINCIPLES | DEBIO RECHERCHE PHARMACEUTIQUE S.A. (CH) | 1999-02-17 | — | — | EP | claimed |
| WO-1998055101-A1 | IMPLANTS FOR CONTROLLED RELEASE OF PHARMACEUTICALLY ACTIVE PRINCIPLES AND METHOD FOR MAKING SAME | DEBIO RECHERCHE PHARMACEUTIQUE S.A. (CH) | 1998-12-10 | — | — | WO | claimed |
| WO-1998010786-A2 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SYNDROME X OF REAVEN | COHEN YAROM (IL) | 1998-03-19 | — | — | WO | claimed |
| WO-1997047317-A1 | COMBINATION OF A SOMATOSTATIN ANALOGUE AND A RAPAMYCIN | NOVARTIS AG (CH) | 1997-12-18 | — | — | WO | claimed |
| EP-0808153-A1 | METHOD AND DEVICE FOR ADMINISTERING ANALGESICS | MEDTRONIC, INC. (US) | 1997-11-26 | — | — | EP | claimed |
| WO-1997041836-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE SUSTAINED RELEASE OF INSOLUBLE ACTIVE PRINCIPLES | DEBIO RECHERCHE PHARMACEUTIQUE S.A. (CH) | 1997-11-13 | — | — | WO | claimed |
| WO-1996024330-A1 | METHOD AND DEVICE FOR ADMINISTERING ANALGESICS | MEDTRONIC, INC. (US) | 1996-08-15 | — | — | WO | claimed |